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Background: Treatments of eating disorders result too often in partial psychological and physical remission,
chronicization, dropout, relapse and death, with no fully known explanations for this failure. In order to clarify this
problem, we conducted three studies to identify the biochemical background of cognitive-behavioural psychotherapy
(CBT), individual psychology brief psychotherapy (IBPP), and psychotherapy-pharmacotherapy with CBT + olanzapine in
anorexics (AN) and bulimics (BN) by measuring the levels of plasma homovanillic acid (HVA) for dopamine secretion,
plasma 3-methoxy-4-hydroxy-phenylglycol (MHPG) for noradrenalin secretion, and platelet [3H]-Paroxetin-binding
Bmax and Kd for serotonin transporter function. The data were then compared with psychopathological and
physical alterations.
Methods: Study 1 investigated the effects of 4 months of CBT on plasma HVA, MHPG and [3H]-Par-binding in 14
AN-restricted, 14 AN-bingeing/purging, and 22 BN inpatients. Study 2 investigated the effects of 4 months of IBPP
on plasma HVA in 15 AN and 17 BN outpatients. Study 3 investigated the effect of 3 months of CBT + olanzapine
(5 mg/day) in 30 AN outpatients. The data were analyzed using one-way ANOVA for repeated measures for the
changes between basal and post-treatment biological and psychological parameters, two-way ANOVA for repeated
measures for the differences in the psychobiological data in the 3 groups, Spearman’s test for the correlations between
basal and final changes in the psychological and biological scores.
Results: Study 1 revealed significant amelioration of the psychopathology in the AN and BN patients, no effects on
HVA, MHPG or Paroxetin binding Kd, and a significant increase in Par-binding Bmax only in the BN patients. Study 2
revealed a significant effect of IBPP on psychopathology in the AN and BN patients, and a significant increase in HVA only
in the BN patients. Study 3 revealed a significant positive effect of CBT + olanzapine therapy on the psychopathology and
increased HVA values. No correlations were observed in the 3 groups between biological and psychological effects of the
three treatments.
Conclusions: Our data advance suggestions on the mechanism of action of the three therapies; however, the lack of
correlations between biochemical and psychological effects casts doubt on their significance.
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The treatment of Eating Disorders (ED), including anorexia
nervosa (AN), bulimia nervosa (BN), and binge eating
disorder (BED), is a complex multivariate process which
comprises nutritional rehabilitation, psychotherapy, psycho-
pharmacotherapy, and treatment of the medical complica-
tions that develop during the course of the disease and that
may interfere with its development and prognosis [1-5].
Each treatment is directed at correcting distinct parts of the
disorders and each is essential for successful outcome, none
being omnivalent or sufficient by itself to induce full recov-
ery, though combined use of multiple therapies is reported
to be effective in the treatment of ED. However, they mostly
correct the pathological eating behaviour, often leaving
out the psychological background which is the likely cause
of the diseases. In other words, each treatment takes into
consideration a group of symptoms or specific aspects but
not the core of the diseases. This may be because the basic
cause or the core of ED is still not clear. And in spite of
extensive of brain imaging studies identifying the areas
pathologically involved in ED [6-8], the brain’s biochem-
ical background behind the onset and course of these
disorders has not been clarified, leaving the question open
as to which basic therapy could potentially correct it.
Some brain biological alterations present during the
course of ED are well known and have been intensively
studied. But we still do not know whether they precede
these disorders, being their cause, or whether they develop
and progress during their course, perhaps subsequent to
the nutritional alterations characterizing ED, such as the
food deficiencies specific for AN in particular and also
in part for BN. What we do know is that the functions
of the brain’s serotoninergic, noradrenergic, dopamin-
ergic, acetylcholinergic systems and brain hormonal
and neuropeptide secretion are frankly impaired. Yet
we do not know if they are only responsible for specific
symptomatological aspects of the disorders. [9-14]. Simi-
larly, neuroimaging studies have identified the brain areas
whose functions are altered in ED [15-17], mostly in terms
of hypo- or hyperfunction, but less is known about the
biological meanings of the hypo- or hyper function of
these brain nuclei, which raises further questions as to the
biochemical impairments that occur with regard to the
role neurotransmitters, neurohormones, neuropeptides and
most of their receptors in these areas play in the psycho-
pathological alterations related to these syndromes. Hence,
the pathogenetic treatment of AN, BN and BED remains
a matter of debate. Should DEB be corrected, if possible,
by modifying the genetic impairments and the brain’s
biochemical alterations that might be the background of
the disorders or just by dealing with the full-blown
symptomatology of ED?
Up to now, most treatments have included behavioural
and physical rehabilitation, taking into considerationcorrection of the distorted eating attitude but only
partially the psychological impairments behind it. What-
ever the therapeutic approach, the results are generally
insufficient and the recovery partial, followed too often
by relapses and chronicization of the diseases.
At this point, a possible validation of specific thera-
peutic interventions should first include investigation of
the brain’s biochemical impairments that have been
reported to consistently occur in ED to see whether and
how they correlate with the psychopathology of the
disorders, and whether they change or disappear during
or after treatment, in parallel with specifically correlated
psychopathological aspects, ultimately resulting in full
contemporary recovery of the psychopathological, behav-
ioural and physical alterations of the diseases.
Following this line of reasoning, we conducted three
types of experiments in which we looked at the psycho-
pathological, behavioural and physical aspects of ED
and, in parallel, at the concentrations of the peripheral
metabolites of noradrenalin and dopamine and at sero-
tonin function, as expressed by the serotonin transporter
evaluated by platelet paroxetine binding, before and after
psychotherapeutic, psychopharmacological and physical
treatments. Our aim was to see whether or not it was
possible to find a connection between the brain’s bio-
chemical impairments and specific psychopathological
aspects of the diseases, and whether our treatments could
correct the brain neurotransmitter alterations in parallel
with the psychophysical pathology of the diseases.
Methods
Study 1
The first study investigated the effects of nutritional
rehabilitation associated with Fairburn transdiagnostic
cognitive-behavioural therapy (CBT) [18], as adapted to
make it suitable for an inpatient setting by Dalle Grave
[19], on the secretion of brain dopamine (DA), noradrena-
lin (NE) and serotonin (5-HT) in a group of 50 female
inpatients, 14 with AN restricted type (AN-R), 14 with the
bingeing-purging type (AN-BP), and 22 with BN. Written
informed consent for participation in the study was
obtained from participants. Patients were all hospitalized
at Villa Garda, Garda, Italy. The study was performed in
compliance with the Helsinki declaration and the approval
of the hospital ethics committee. The brain neurotrans-
mitter functions were examined by peripheral measure-
ment of the main neurotransmitter metabolites: plasma
homovanillic acid (HVA) for DA; plasma 3-methoxy-4-
hydroxyphenylglycol (MHPG) for NE; and for 5-HT the
platelet 5-HT-transporter evaluated by paroxetine binding
([3H ]-Par-binding), divided in Bmax (maximum binding
capacity) and Kd (dissociation constant). HVA, MHPG,
and Par-binding values have been amply demonstrated
to closely mirror the central secretion of the three
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measure of neurotransmitter function [20-23]. The aim of
the study was to see whether or not NE-DA neurotrans-
mitter metabolites and [3H]-Par-binding are linked to
specific aspects of the two diseases, if CBT modifies their
secretion, if the physical, behavioural and psychological
effects of CBT correlate with changes in neurotransmitter
secretions, and if the biological effects of CBT are linked
to specific psychopathological aspects of the disorders.
All 50 patients were women. The mean age of patients
was 27 ± 7 years in the AN-R group, 22 ± 4 years in the
AN-BP group, and 30 ± 8 years in the BN group. The mean
duration of disease was 126 ± 50 months in the AN-R
group, 120 ± 72 months in the AN-BP group, and 108 ±
60 months in the BN group. The mean body-mass index
([BMI] was 14 ± 1 in the AN-R group, 16 in the AN-BP
group, and 19 in the BN group; the mean binging-purging
frequency was 10 episodes a week in the AN-BP group and
16 episodes a week in the BN group. All the AN patients
were amenorrheic, BN patients were in the follicular
phase of the cycle.
The specific psychopathological aspects of the disorders
were assessed according to the following instruments:
EDE 12-OD, depression by the Beck Depression Inventory
(BDI), anxiety by the STAI Form-Y-1, impulsiveness by
the Barratt Impulsiveness Scale version 11 (BIS 11), self-
esteem by the Rosenberg Self-Biochemical Scale (RSBS),
and personality characteristics by the Temperament and
Character Inventory-Cloninger Scale (TCI, short form of
the 240 items). The biological, physical and psychological
measures were assessed at baseline and at the end of
20 weeks of CBT treatment divided into 13 weeks of
inpatient treatment followed by 7 weeks of residential
day-hospital.
Written informed consent to participate to the study
according to the Helsinki declaration was obtained by
patients. The study protocol was approved by the insti-
tutional Review Board of Villa Garda Hospital, Verona,
Italy. The Clinical Trials.gov. Identifier number was
NCT01990755.
HVA and MHPG were measured by high-liquid gas
chromatography (HPLC) followed by dual-electrode colori-
metric electrochemical detection as previously described
[24]. [3H] Par binding was measured by spectrometry
according to the method of Marazziti et al. [20] as previ-
ously described.
The Clinical Trials gov. identifier number was NCT
01990755.
Study 2
This study investigated the effects in 15 AN and 17 BN
outpatients of the Psychiatry University Department,
Torino-Italy of an individual psychology brief psycho-
therapy (IBPP) [25] on psychological alterations and DAsecretion measured as peripheral blood values of HVA
before and after treatment. The study was performed in
compliance with the Helsinki declaration, and approved
by the university ethics committee.
The mean age of the patients was 20 ± 3.5 years in the
AN group and 22 ± 2.8 years in the BN group. The mean
duration of disease was 13 ± 8 years in the AN group
and 11 ± 4 years in the BN group. The mean BMI was
16 ± 1 in the AN group and 21 ± 2 in the BN group. The
duration of IBPP was 4 months. The psychopathological
aspects were assessed using the EDI-2, SCL-90, TCI at
baseline and after 4 months of therapy. Written in-
formed consent for participation in the study accord-
ing to the Helsinki declaration was obtained from all
subjects. The study protocol was approved by the
institutional Review Board of the Psychiatry Department,
Turin University, Italy. The Clinical Trials.gov.Identifier
number was NCT01990755.
Study 3
The study evaluated in AN-R and AN-BP patients of the
San Paolo Hospital, Milan, Italy, the effects of CBT and
of CBTassociated with orally administered 5 mg olanzapine
on the psychopathological aspects of the disease and on the
secretion of HVA to see whether a correlation could be
observed between biochemical and psychological disorders
typical of ED. The study was performed in compliance with
the Helsinki declaration and approved by the hospital ethics
committee.
The probands were 18 AN-R and 12 AN-BP patients
of the University Dept. of Psychiatry, Milano, Italy. Mean
age of the participants was 25 ± 6 years; the mean duration
of disease was 5.5 ± 4 years; and the mean BMI was 15 ± 1.
All were outpatients and all underwent a 3-month course
of CBT, with one half randomly assigned and double-
blinded to receive oral olanzapine (2.5 mg for 1 month,
5 mg for 2 months) and the other half an oral placebo.
BMI, HVA and psychopathological aspects of the patients
were monitored before and at 3 months of therapy by
means of the EDI-2, the Hamilton Rating Scale for
Depression (HRSD), the Buss-Durkee Rating Scale for
aggressiveness (BDRS), the TCI for temperament and
character aspects, and the Yale-Brown Cornell for Eating
Disorders (YBCS) for obsessivity-compulsivity.
Written informed consent to participate to the study ac-
cording to the Helsinki declaration was obtained from all
subjects. The study protocol was approved by the Institu-
tional Review Board of The Sacco Hospital, Milano, Italy.
The Clinical Trials.gov.Identifier number was NCT
01990755.
Statistical analyses
The data were analyzed using one-way ANOVA for
repeated measures to evaluate the significance of the
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between baseline and post-treatment, and by two-way
ANOVA for repeated measures to evaluate the differ-
ences in the psychological and biological data in the
three groups. The Spearman test was used to evaluate
the correlations between basal and final changes in the
psychological and biological scores.
Results
Study 1
CBT significantly improved the physical aspects of the
diseases, particularly BMI in the AN-R and AN-BP
patients, and significantly reduced or totally interrupted
binging-purging frequency in the AN-BP and BN patients.
Psychological assessment revealed that at the end of treat-
ment the ED symptoms, depression, anxiety, impulsive-
ness and self-esteem improved across all three groups, but
more significantly so in the BN than in the AN group.
The basal (T0) and final (T1) HVA and MHPG values
(Table 1) did not differ significantly in the three groups
and decreased but not significantly in all three groups
after the end of CBT. Basal and final Par-binding Bmax
values did not differ significantly in the three groups and
did not change significantly in the AN-R and AN-BP
patients, whereas a significant increase was observed in
the BN patients. Basal and final Par-binding Kd did not
differ significantly in the three groups, and no significant
changes were observed in any of the three groups between
basal and final values. Basal and final psychological and
biochemical data did not correlate. When the difference
(Δ) between the basal and final values of neurotransmitter
and psychological scores was taken into consideration,
no significant correlations were observed between the
psychological and the biochemical data.Table 1 Effects of CBT on HVA, MHPG and [3H]
paroxetine-binding values in AN and BN patients
AN-R AN-BP BN
HVA (ng/ml)
basal 17.4 ± 9.0 16.6 ± 8.8 15.6 ± 10.2
after therapy 15.6 ± 9.8 12.7 ± 6.0 14.1 ± 9.6
MHPG (ng/ml)
basal 10.4 ± 27.1 5.3 ± 4.0 4.4 ± 1.9
after therapy 4.4 ± 4.2 4.1 ± 3.8 3.4 ± 1.7
[3H]-PAR-Bmax (fmol/
mg protein) basal 446 ± 100 512 ± 175 432 ± 133
after therapy 602 ± 161 551 ± 306 645 ± 121*
[3H]-PAR-Kd (nmol/L)
basal 0.34 ± 0.48 0.31 ± 0.43 0.26 ± 0.34
after therapy 0.24 ± 0.38 0.64 ± 0.14 0.05 ± o.004
Plus-minus values are the means ± SD.
*p = 0.04, r = 1.Study 2
At the end of treatment with IBPP the BMI increased
significantly over baseline in the AN patients (16 ± 1 vs.
21 ± 2, P <0.001) but was unchanged in the BN patients.
Bingeing-purging frequency was consistently reduced in
both the AN and BN groups. Psychological impairments
after therapy improved in both the AN and BN groups.
With regard to the biochemical data (Table 2), HVA
values before therapy did not differ in the AN and BN
patients and did not change after treatment in the AN
patients but increased significantly in the BN patients.
No significant correlations were observed between the
psychometric test scores and the HVA values before and
after therapy, nor between the changes in the two pa-
rameters between the two time points, except for some
temperamental aspects whose changes showed a positive
correlation with those of the DA metabolite, as repre-
sented by reward dependence in particular (P <0.02) in
both the AN and BN patients, harm avoidance in the AN
(P <0.04) and BN patients (P <0.008), self-directedness in
the BN patients (P <0.04), self-transcendence in the BN
patients (P <0.007) and cooperativeness in the AN and BN
patients (P <0.06).
Study 3
At the end of 3 months of treatment with CBT and olan-
zapine (Table 3), the BMI increased consistently in the
AN patients without a significant difference between the
CBT and the CBT + olanzapine-treated patients (16.2 ± 1
vs. 21.4 ± 2.3; P >0.001). Bingeing-purging frequency was
also reduced. The psychopathological symptoms including
most of the specific aspects related to eating pathology of
the disease improved consistently with both treatments,
albeit without significant differences between the two
groups, while olanzapine administration significantly im-
proved obsessivity-compulsivity, depression, anxiety and
especially hostility (Table 3). HVA blood levels increased
significantly in the CBT + olanzapine group, and were un-
changed in the CBT group. No correlations were observed
between HVA concentrations and the psychopathological
parameters examined before and after therapy, nor the
changes between the two parameters.
Discussion
Even though preliminary the results of our three studies
are intriguing. In each of them the psychopathology andTable 2 Effects of IBPP therapy on HVA secretion in AN
and BN patients
AN BN
basal 6.9 ± 2.3 8.1 ± 1,8
after therapy 7.6 ± 1.6 11,3 ± 3.3 *
*p < 0.000.
Plus-minus values are the means ± SD.
Table 3 Effect of CBT + olanzapine or placebo on HVA
secretion in anorexia nervosa
patients T0 T 1 p F d.f
Olanzapine 0.4 ± 0.3 1.1 ± 1.5 0.04 3.6 3
Placebo 0.4 ± 0.1 0.3 ± 0.1 NS
Plus-minus values are the means ± SD.
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by CBT or IBPP in the bulimics and somewhat less in
the anorexics, while olanzapine treatment seemed to act
significantly mostly on comorbid depression, anxiety,
obsessivity-compulsivity and hostility, suggesting that a
dopaminergic deficiency could be the background of co-
morbidities more than of a specific ED symptomatology.
However, the effects of the three treatments on NE,
DA and 5-HT functions are difficult to interpret. The
HVA and MHPG values in Study 1 did not change
under CBT in either the AN or BN patients, suggesting
that the therapeutic effects of this type of psychotherapy
are probably not related to catecholamine function, and
that the observed improvements in the altered nutri-
tional behaviour and related psychopathology may not
be linked to increases in previously deficient NE and DA
secretions. This was suggested also by the observation
that when the basal and post-treatment neurotransmitter
Δ-values and Δ-psychological scores were correlated no
significant correlations were observed between Δ-HVA
or Δ-MHPG and Δ-psychopathological aspects of the
diseases. With regard to [3H]-Paroxetine-binding Bmax
and Kd, the observation that CBT increased 5-HT trans-
porter maximum binding capacity in the BN but not in
the AN patients is interesting, since impaired 5-HT
brain function has been reported in both AN and BN
patients but only BN patients have been reported to
show a clear-cut psychopathological recovery after
psychotherapy [5,23,26-29], which could be related to
the 5-HT transporter improvement we observed. The fact
that we could not find specific significant correlations
between improvement in 5-HT function and a significant
reduction in ED psychopathology in the bulimics, how-
ever, seems to exclude that the positive psychophysical
effects of CBT are linked to a global correction of 5-HT
function.
Two points seem to contradict the correction secretory
hypothesis. First, the Par-binding improvement is incom-
plete regarding the binding capacity of the transporter but
not its dissociation constant, thus casting doubt on a
global regulatory effect of CBT on 5-HT. Second, the lack
of a correlation between the Par-binding-Bmax increase
and improvement in BN-specific psychopathology of
our patients would suggest that the two improvements,
biological and psychopathological, are not linked to one
another and therefore that the BN-specific psychological
alterations are not linked to a serotonin deficiency. Itshould be remarked that the rating scales we used to
measure the psychopathology of our patients may have
missed important aspects of BN and that correlations
between 5-HT secretion and clinical symptoms might
have appeared if other aspects of the disorder had been
taken into consideration. The same observation holds
for the type of assay of 5-HT function we used, since
Par-binding measures the function of 5-HT transporter
and not the direct secretion of 5-HT and its metabolites,
5-HT receptors density and function. All these points
should be considered and investigated to evaluate the
meaning of our results.
The data from Study 2 are also intriguing. While IBPP
was frankly effective on the psychological and behavioural
alterations of both AN and BN patients, no changes were
observed in HVA secretion in the AN patients, while
increased secretion of the DA metabolite was observed
in the BN patients. Again, no correlations between the
biochemical and psychological aspects of the disorders
were observed in either group, except for temperamental
characters whose changes under the IBPP therapy revealed
a positive correlation with the increase in HVA in both
groups. Hence, it may be conjectured that a DA deficiency
in AN and BN is not involved in their specific psychological
and behavioural pathologies, being instead the possible
background of the temperamental alterations which, on
the other hand, have been suggested as one of the basic
components in ED etiopathogenesis. Obviously, the same
objections to our methodology reported for Study 1 can
be raised here too. In both studies we used a large variety
of rating scales to investigate the entire spectrum of the
psychopathological aspects of AN and BN, including the
premorbid temperamental characters of the patients, and
the psychological, behavioural and comorbid aspects of
the full-blown AN and BN pathologies. This does not
exclude that our investigation might have missed other
psychopathological aspects more significantly improved
by IBPP treatment and possibly better correlating with a
DA-dependent psychopathology. Moreover, HVA is a mir-
ror of DA secretion but not of DA pre- and postsynaptic
receptor activity, which means that we cannot exclude an
effect of IBPP on DA system function and aspects we did
not take into consideration.
The results of Study 3 are even more intriguing. While
CBT significantly improved the specific psychopathology
of our patients, olanzapine administration seemed to act
mostly on the associated comorbidities like depression,
anxiety, hostility and obsessivity-complsivity. Again, a
lack of correlation between increased DA activity and
decreased AN-specific and unspecific psychopathology
seems to exclude the possibility that a DA dysfunction
in AN is involved in the pathogenesis of the disorder
and its possible recovery. Altered DA secretion has been
suggested to be involved in the etiopatogenesis of ED
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in the past with classical psychotropic drugs acting on DA
secretion and receptor functions have not yielded positive
results [5,35-37]. More recently, atypical psychotropic drugs
including olanzapine, quetiapine, risperidol, clozapine,
aripiprazole have been administered [5,38], again, with
inconsistent effects. In these therapeutic approaches,
drug absorption and its effects on manipulating DA
secretion and DA receptor response were not controlled.
Study 3 demonstrated that while olanzapine does stimulate
DA secretion it does not seem to influence AN-specific
psychopathology. But as we did not investigate its pre- and
postsynaptic receptor function, we cannot exclude that the
lack of efficacy of the drug was not due to postsynaptic
receptor insensitivity.
Limits of our studies include the relatively small samples
of patients examined, which reduces the generalization of
the results and did not permit the subgrouping of the
samples in the diagnostic subtypes. A second limit is
represented by the choice of running each experiment in
different centres. This was due to the necessity of finding
in a relatively short time a sufficient number of patients
with a perfectly well defined diagnosis.
Conclusions
At this point we should admit that our approach did not
fully elucidate the biochemical impairments potentially
underlying ED nor did it further our understanding of
the background and significance of the effects of our
therapeutic approaches. In particular, we were unable to
define clear-cut correlations between the therapeutically-
induced changes of basal NE, DA and 5-HT metabolites
and of the specific psychopathological aspects of the two
disorders. In brief, our protocol of investigation did not
help us to better define the brain biochemical background
of ED therapies or provide convincing evidence for which
type of therapy to suggest. Possibly, other biochemical
alterations should be examined in parallel, including
hormones, peptides, multiple biochemical parameters
expressions of the brain metabolic function together
with anatomical alterations of specific brain centers. In
other words, a protocol of investigation including the
relationship between biochemical and psychological aspects
of the patients should be always at the basis of the diagnos-
tic and therapeutic approaches to ED.
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